Novel computational approaches to polypharmacology as a means to define responses to individual drugs

Annual Review of Pharmacology and Toxicology

Volumn 52, Issue , 2012, Pages 361-379

  Xie, Lei ^a   Xie, Li ^b   Kinnings, Sarah L ^c   Bourne, Philip E ^b  

^a City University of New York   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug target network; Dynamic simulation; In vivo efficacy; Metabolic modeling; Protein ligand interaction

Indexed keywords

PROTEOME;

ARTICLE; BINDING AFFINITY; DRUG RESPONSE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MATHEMATICAL ANALYSIS; MOLECULAR INTERACTION; MOLECULAR MODEL; PHARMACOLOGY; PHENOTYPE; POLYPHARMACOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN DNA INTERACTION; PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIMULATION; STOICHIOMETRY;

ANIMALS; COMPUTATIONAL BIOLOGY; COMPUTER SIMULATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG DISCOVERY; DRUG INTERACTIONS; GENE REGULATORY NETWORKS; HUMANS; LIGANDS; PHENOTYPE; PROTEOMICS;

EID: 84855882587     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010611-134630     Document Type: Article

References (141)

1. Jain MK, Ridker PM. 2005. Anti-inflammatory effects of statins: clinical evidence and basicmechanisms. Nat. Rev. Drug Discov. 4:977-87
2. Xie L, Li J, Xie L, Bourne PE. 2009. Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of CETP inhibitors. PLoS Comput. Biol. 5:e1000387
3. Hopkins AL, Mason JS, Overington JP. 2006. Can we rationally design promiscuous drugSá Curr. Opin. Struct. Biol. 16:127-36 (Pubitemid 43221881)
4. Hopkins AL. 2007. Network pharmacology. Nat. Biotechnol. 25:1110-11 (Pubitemid 47538107)
5. Lu L, Payvandi F, Wu L, Zhang LH, Hariri RJ, et al. 2009. The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. Microvasc. Res. 77:78-86
6. Lange RP, Locher HH, Wyss PC, Then RL. 2007. The targets of currently used antibacterial agents: lessons for drug discovery. Curr. Pharm. Des. 13:3140-54 (Pubitemid 350130963)
7. Kitano H. 2007. A robustness-based approach to systems-oriented drug design. Nat. Rev. Drug Discov. 6:202-10 (Pubitemid 46344624)
8. Hopkins AL. 2008. Network pharmacology: the next paradigm in drug discovery. Nat. Chem. Biol. 4:682-90
9. Knight ZA, Lin H, Shokat KM. 2010. Targeting the cancer kinome through polypharmacology. Nat. Rev. Cancer 10:130-37
10. Antman EM,DeMetsD, Loscalzo J. 2005. Cyclooxygenase inhibition and cardiovascular risk. Circulation 112:759-70 (Pubitemid 41099056)
11. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M. 2007. Drug-target network. Nat. Biotechnol. 25:1119-26 (Pubitemid 47538114)
12. Paolini GV, Shapland RH, van HoornWP, Mason JS, Hopkins AL. 2006. Global mapping of pharmacological space. Nat. Biotechnol. 24:805-15 (Pubitemid 44086621)
13. Mestres J, Gregori-Puigjane E, Valverde S, Sole RV. 2008. Data completeness-the Achilles heel of drug-target networks. Nat. Biotechnol. 26:983-84
14. Kinnings SL, Xie L, Fung K, Xie L, Bourne PE. 2010. The Mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comp. Biol. 6:e100976
15. Nobeli I, Favia AD, Thornton JM. 2009. Protein promiscuity and its implications for biotechnology. Nat. Biotechnol. 27:157-67
16. Ji HF, Kong DX, Shen L, Chen LL, Ma BG, Zhang HY. 2007. Distribution patterns of small-molecule ligands in the protein universe and implications for origin of life and drug discovery. Genome Biol. 8:R176
17. Li X, Gianoulis TA, Yip KY, Gerstein M, Snyder M. 2010. Extensive in vivo metabolite-protein interactions revealed by large-scale systematic analyses. Cell 143:639-50
18. Dobson PD, Patel Y, Kell DB. 2009. 'Metabolite-likeness' as a criterion in the design and selection of pharmaceutical drug libraries. Drug Discov. Today 14:31-40
19. Yan Q. 2010. Membrane transporters and drug development: relevance to pharmacogenomics, nutrigenomics, epigenetics, and systems biology. Methods Mol. Biol. 637:1-21
20. Veith H, Southall N, Huang R, James T, Fayne D, et al. 2009. Comprehensive characterization of cytochrome P450 isozyme selectivity across chemical libraries. Nat. Biotechnol. 27:1050-55
21. Bouman HJ, Schomig E, vanWerkum JW, Velder J, Hackeng CM, et al. 2010. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med. 17:110-16
22. Piddock LJ. 2006. Multidrug-resistance efflux pumps-not just for resistance. Nat. Rev. Microbiol. 4:629-36 (Pubitemid 44317025)
23. Lewis K. 1994. Multidrug resistance pumps in bacteria: variations on a theme. Trends Biochem. Sci. 19:119-23 (Pubitemid 24082789)
24. Fletcher JI, Haber M, Henderson MJ, Norris MD. 2010. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 10:147-56
25. Baysarowich J, Koteva K, Hughes DW, Ejim L, Griffiths E, et al. 2008. Rifamycin antibiotic resistance by ADP-ribosylation: structure and diversity of Arr. Proc. Natl. Acad. Sci. USA 105:4886-91 (Pubitemid 351753841)
26. Weinshilboum RM, Wang L. 2006. Pharmacogenetics and pharmacogenomics: development, science, and translation. Annu. Rev. Genomics Hum. Genet. 7:223-45 (Pubitemid 44627929)
27. Poulikakos PI, Zhang C, Bollag G, ShokatKM, RosenN. 2010. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464:427-30
28. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. 2010. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140:209-21
29. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, et al. 2010. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464:431-35
30. Wu M, Pastor-Pareja JC, Xu T. 2010. Interaction between RasV12 and scribbled clones induces tumour growth and invasion. Nature 463:545-48
31. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. 2009. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 459:428-32
32. Kong HJ,Mooney DJ. 2007. Microenvironmental regulation of biomacromolecular therapies. Nat. Rev. Drug Discov. 6:455-63 (Pubitemid 47064568)
33. Koschny R, Walczak H, Ganten TM. 2007. The promise of TRAIL-potential and risks of a novel anticancer therapy. J. Mol. Med. 85:923-35 (Pubitemid 47282789)
34. Mestres J, Gregori-Puigjane E. 2009. Conciliating binding efficiency and polypharmacology. Trends Pharmacol. Sci. 30:470-74
35. Rees DC, Congreve M, Murray CW, Carr R. 2004. Fragment-based lead discovery. Nat. Rev. Drug Discov. 3:660-72 (Pubitemid 39173507)
36. Gleeson MP, Hersey A, Montanari D, Overington J. 2011. Probing the links between in vitro potency, ADMET and physicochemical parameters. Nat. Rev. Drug Discov. 10:197-208
37. Garraway LA, Hahn WC. 2010. On or off target: mutations, models, and predictions. Sci. Transl. Med. 2:35ps28
38. Korcsmaros T, Szalay MS, Bode C, Kovacs IA, Csermely P. 2007. How to design multi-target drugs: Target search options in cellular networks. Expert Opin. Drug Discov. 2:799-808 (Pubitemid 47287964)
39. D'Ari R, Casadesus J. 1998. Underground metabolism. BioEssays 20:181-86 (Pubitemid 28132113)
40. Akitaya T, Seno A, Nakai T, Hazemoto N, Murata S, Yoshikawa K. 2007. Weak interaction induces an ON/OFF switch, whereas strong interaction causes gradual change: folding transition of a long duplex DNA chain by poly-L-lysine. Biomacromolecules 8:273-78 (Pubitemid 46140502)
41. Tanay A. 2006. Extensive low-affinity transcriptional interactions in the yeast genome. Genome Res. 16:962-72 (Pubitemid 44162255)
42. Segal E, Raveh-Sadka T, SchroederM,Unnerstall U, Gaul U. 2008. Predicting expression patterns from regulatory sequence in Drosophila segmentation. Nature 451:535-40 (Pubitemid 351186263)
43. Badis G, Berger MF, Philippakis AA, Talukder S, Gehrke AR, et al. 2009. Diversity and complexity in DNA recognition by transcription factors. Science 324:1720-23
44. Zhai D, Jin C, Satterthwait AC, Reed JC. 2006. Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins. Cell Death Differ. 13:1419-21 (Pubitemid 44057478)
45. Roy J, Cyert MS. 2009. Cracking the phosphatase code: docking interactions determine substrate specificity. Sci. Signal. 2:re9
46. Legate KR, Wickstrom SA, Fassler R. 2009. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 23:397-418
47. Cheng Y, LeGall T, Oldfield CJ, Mueller JP, Van YY, et al. 2006. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 24:435-42 (Pubitemid 44374778)
48. Agoston V, Csermely P, Pongor S. 2005. Multiple weak hits confuse complex systems: a transcriptional regulatory network as an example. Phys. Rev. E 71:051909
49. Csermely P. 2004. Strong links are important, but weak links stabilize them. Trends Biochem. Sci. 29:331-34 (Pubitemid 38968747)
50. Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, et al. 2008. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science 320:539-43 (Pubitemid 351590668)
51. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, et al. 2008. An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807-12
52. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, et al. 2008. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801-6
53. Ames BN. 2006. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proc. Natl. Acad. Sci. USA 103:17589-94 (Pubitemid 44852204)
54. Xie L, Evangelidis T, Xie L, Bourne PE. 2011. Drug discovery using chemical systems biology: Weak inhibition of multiple kinases may contribute to the anti-cancer effect of Nelfinavir. PLoS Comp. Biol. 7:e1002037
55. Lipton SA. 2004. Turning down, but not off. Nature 428:473 (Pubitemid 38480520)
56. Youdim MB, Buccafusco JJ. 2005. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 26:27-35 (Pubitemid 40052707)
57. Nash P, Tang X, Orlicky S, Chen Q, Gertler FB, et al. 2001. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414:514-21 (Pubitemid 33131529)
58. Justman QA, Serber Z, Ferrell JE Jr, El-Samad H, Shokat KM. 2009. Tuning the activation threshold of a kinase network by nested feedback loops. Science 324:509-12
59. Buchert M, Athineos D, Abud HE, Burke ZD, Faux MC, et al. 2010. Genetic dissection of differential signaling threshold requirements for theWnt/β-catenin pathway in vivo. PLoS Genet. 6:e1000816
60. Copeland RA, Pompliano DL, Meek TD. 2006. Drug-target residence time and its implications for lead optimization. Nat. Rev. Drug Discov. 5:730-39 (Pubitemid 44323700)
61. Lu H, Tonge PJ. 2010. Drug-target residence time: critical information for lead optimization. Curr. Opin. Chem. Biol. 14:467-74
62. Braz VA, Holladay LA, Barkley MD. 2010. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers. Biochemistry 49:601-10
63. Lu H, England K, am Ende C, Truglio JJ, Luckner S, et al. 2009. Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol. 4:221-31
64. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, et al. 2008. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat. Chem. Biol. 4:691-99
65. Morphy R, Rankovic Z. 2007. Fragments, network biology and designing multiple ligands. Drug Discov. Today 12:156-60 (Pubitemid 46176667)
66. Jia J, Zhu F, Ma X, Cao Z, Li Y, Chen YZ. 2009. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8:111-28
67. Calzolari D, Bruschi S, Coquin L, Schofield J, Feala JD, et al. 2008. Search algorithms as a framework for the optimization of drug combinations. PLoS Comput. Biol. 4:e1000249
68. Brown RD, Martin YC. 1996. Use of structure-activity data to compare structure-based clustering methods and descriptors for use in compound selection. J. Chem. Inf. Comput. Sci. 36:572-84 (Pubitemid 126539358)
69. Varnek A, Tropsha A. 2008. Chemoinformatics: An Approach to Virtual Screening. Cambridge, UK: R. Soc. Chem.
70. Schneider P, Tanrikulu Y, Schneider G. 2009. Self-organizingmaps in drug discovery: compound library design, scaffold-hopping, repurposing. Curr. Med. Chem. 16:258-66
71. Nidhi, Glick M, Davies JW, Jenkins JL. 2006. Prediction of biological targets for compounds using multiple-category Bayesian models trained on chemogenomics databases. J. Chem. Inf. Model. 46:1124-33 (Pubitemid 43999157)
72. Keiser MJ, Roth BL, Armbruster BN, Ernsberger P, Irwin JJ, Shoichet BK. 2007. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25:197-206 (Pubitemid 46227119)
73. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, et al. 2009. Predicting new molecular targets for known drugs. Nature 462:175-81
74. Schneider G. 2010. Virtual screening: an endless staircase? Nat. Rev. Drug Discov. 9:273-76
75. Ballester PJ, Finn PW, Richards WG. 2009. Ultrafast shape recognition: evaluating a new ligand-based virtual screening technology. J. Mol. Graph. Model. 27:836-45
76. Ballester PJ, Westwood I, Laurieri N, Sim E, Richards WG. 2010. Prospective virtual screening with Ultrafast Shape Recognition: the identification of novel inhibitors of arylamine N-acetyltransferases. J. R. Soc. Interface 7:335-42
77. Rush TS III, Grant JA, Mosyak L, Nicholls A. 2005. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. J. Med. Chem. 48:1489-95 (Pubitemid 40364556)
78. Jenkins JL, Glick M, Davies JW. 2004. A 3D similarity method for scaffold hopping from known drugs or natural ligands to new chemotypes. J. Med. Chem. 47:6144-59 (Pubitemid 39587240)
79. Jain AN. 2000. Morphological similarity: a 3D molecular similarity method correlated with proteinligand recognition. J. Comput. Aided Mol. Des. 14:199-213 (Pubitemid 30110675)
80. Guner OFE. 2000. Pharmacophore Perception, Development, and Use in Drug Design. La Jolla, CA: Int. Univ. Line
81. Klabunde T, Evers A. 2005. GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR-mediated side effects. ChemBioChem 6:876-89 (Pubitemid 40873749)
82. Lamb J. 2007. The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 7:54-60 (Pubitemid 46020847)
83. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. 2006. The Connectivity Map: using geneexpression signatures to connect small molecules, genes, and disease. Science 313:1929-35 (Pubitemid 44497995)
84. Fliri AF, Loging WT, Volkmann RA. 2009. Drug effects viewed from a signal transduction network perspective. J. Med. Chem. 52:8038-46
85. Bender A, Young DW, Jenkins JL, Serrano M, Mikhailov D, et al. 2007. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. Comb. Chem. High Throughput Screen. 10:719-31 (Pubitemid 350099316)
86. Iorio F, Tagliaferri R, di Bernardo D. 2009. Identifying network of drug mode of action by gene expression profiling. J. Comput. Biol. 16:241-51
87. Iorio F, Bosotti R, Scacheri E, Belcastro V,Mithbaokar P, et al. 2010. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc. Natl. Acad. Sci. USA 107:14621-26
88. Iskar M, Campillos M, Kuhn M, Jensen LJ, van Noort V, Bork P. 2010. Drug-induced regulation of target expression. PLoS Comput. Biol. 6:e1000925
89. Wei G, Twomey D, Lamb J, Schlis K, Agarwal J, et al. 2006. Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 10:331-42 (Pubitemid 44512194)
90. Hu G, Agarwal P. 2009. Human disease-drug network based on genomic expression profiles. PLoS ONE 4:e6536
91. Suthram S, Dudley JT, Chiang AP, Chen R, Hastie TJ, Butte AJ. 2010. Network-based elucidation of human disease similarities reveals common functional modules enriched for pluripotent drug targets. PLoS Comput. Biol. 6:e1000662
92. YoungDW, Bender A, Hoyt J, McWhinnie E, Chirn GW, et al. 2008. Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat. Chem. Biol. 4:59-68 (Pubitemid 350273652)
93. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. 2008. Drug target identification using side-effect similarity. Science 321:263-66 (Pubitemid 351989100)
94. Chen B, Wild D, Guha R. 2009. PubChem as a source of polypharmacology. J. Chem. Inf. Model. 49:2044-55
95. Jiang H, Pritchard JR,Williams RT, Lauffenburger DA, Hemann MT. 2010. A mammalian functionalgenetic approach to characterizing cancer therapeutics. Nat. Chem. Biol. 7:92-100
96. Goh CS, Bogan AA, Joachimiak M, Walther D, Cohen FE. 2000. Co-evolution of proteins with their interaction partners. J. Mol. Biol. 299:283-93
97. Dupont CL, Yang S, Palenik B, Bourne PE. 2006. Modern proteomes contain putative imprints of ancient shifts in trace metal geochemistry. Proc. Natl. Acad. Sci. USA 103:17822-27 (Pubitemid 44852244)
98. Whisstock JC, Lesk AM. 2003. Prediction of protein function from protein sequence and structure. Q. Rev. Biophys. 36:307-40 (Pubitemid 38268660)
99. Xie L, Xie L, Bourne PE. 2011. Structure-based systems biology for analyzing off-target binding. Curr. Opin. Struct. Biol. 21:189-99
100. Chikina MD, Troyanskaya OG. 2011. Accurate quantification of functional analogy among close homologs. PLoS Comput. Biol. 7:e1001074
101. Melvin I, Weston J, Noble WS, Leslie C. 2011. Detecting remote evolutionary relationships among proteins by large-scale semantic embedding. PLoS Comput. Biol. 7:e1001047
102. Yamanishi Y, Araki M, Gutteridge A, HondaW,KanehisaM. 2008. Prediction of drug-target interaction networks from the integration of chemical and genomic spaces. Bioinformatics 24:i232-40 (Pubitemid 351911678)
103. Nagamine N, Shirakawa T, Minato Y, Torii K, Kobayashi H, et al. 2009. Integrating statistical predictions and experimental verifications for enhancing protein-chemical interaction predictions in virtual screening. PLoS Comput. Biol. 5:e1000397
104. VinaD,Uriarte E, Orallo F, Gonzalez-Diaz H. 2009. Alignment-free prediction of a drug-target complex network based on parameters of drug connectivity and protein sequence of receptors. Mol. Pharm. 6:825-35
105. He Z, Zhang J, Shi XH, Hu LL, Kong X, et al. 2010. Predicting drug-target interaction networks based on functional groups and biological features. PLoS ONE 5:e9603
106. Poleksic A. 2009. Algorithms for optimal protein structure alignment. Bioinformatics 25:2751-56
107. Liu W, Srivastava A, Zhang J. 2011. A mathematical framework for protein structure comparison. PLoS Comput. Biol. 7:e1001075
108. Kellenberger E, Schalon C, Rognan D. 2008. How to measure the similarity between protein ligandbinding sites. Curr. Comput. Aided Drug Des. 4:209-20
109. Perot S, Sperandio O, Miteva MA, Camproux AC, Villoutreix BO. 2010. Druggable pockets and binding site centric chemical space: a paradigm shift in drug discovery. Drug Discov. Today 15:656-67
110. Xiong B,Wu J, Burk DL, XueM, Jiang H, Shen J. 2010. BSSF: a fingerprint based ultrafast binding site similarity search and function analysis server. BMC Bioinforma. 11:47
111. Mernberger M, Klebe G, Hullermeier E. 2011. SEGA: Semi-Global Graph Alignment for structurebased protein comparison. IEEE/ACM Trans. Comput. Biol. Bioinforma. 8(5):1330-43
112. Hoffmann B, Zaslavskiy M, Vert JP, Stoven V. 2010. A new protein binding pocket similarity measure based on comparison of clouds of atoms in 3D: application to ligand prediction. BMC Bioinform. 11:99
113. Chen BY, Honig B. 2010. VASP: a volumetric analysis of surface properties yields insights into proteinligand binding specificity. PLoS Comput. Biol. 6:e1000881
114. Halabi N, Rivoire O, Leibler S, Ranganathan R. 2009. Protein sectors: evolutionary units of threedimensional structure. Cell 138:774-86
115. Gao M, Skolnick J. 2010. iAlign: a method for the structural comparison of protein-protein interfaces. Bioinformatics 26:2259-65
116. GaoM, Skolnick J. 2010. Structural space of protein-protein interfaces is degenerate, close to complete, and highly connected. Proc. Natl. Acad. Sci. USA 107:22517-22
117. Bouvier B, Grunberg R, Nilges M, Cazals F. 2009. Shelling the Voronoi interface of protein-protein complexes reveals patterns of residue conservation, dynamics, and composition. Proteins 76:677-92
118. Zhang QC, Petrey D, Norel R, Honig BH. 2010. Protein interface conservation across structure space. Proc. Natl. Acad. Sci. USA 107:10896-901
119. Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, et al. 2008. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36:D901-6 (Pubitemid 351149842)
120. Chen X, Ji ZL, Chen YZ. 2002. TTD: Therapeutic Target Database. Nucleic Acids Res. 30:412-15 (Pubitemid 34679600)
121. Gunther S,KuhnM,DunkelM,CampillosM, SengerC, et al. 2008. SuperTarget and Matador: resources for exploring drug-target relationships. Nucleic Acids Res. 36:D919-22 (Pubitemid 351149845)
122. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK. 2007. BindingDB: aWeb-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 35:D198-201 (Pubitemid 46056198)
123. Wang Y, Xiao J, Suzek TO, Zhang J,Wang J, Bryant SH. 2009. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 37:W623-33
124. Seiler KP, George GA, Happ MP, Bodycombe NE, Carrinski HA, et al. 2008. ChemBank: a smallmolecule screening and cheminformatics resource database. Nucleic Acids Res. 36:D351-59 (Pubitemid 351149748)
125. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, et al. 2001. Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J. 1:167-70 (Pubitemid 33756654)
126. Kuhn M, Szklarczyk D, Franceschini A, Campillos M, von Mering C, et al. 2009. STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res. 38:D552-56
127. von Eichborn J, Murgueitio MS, Dunkel M, Koerner S, Bourne PE, Preissner R. 2010. PROMISCUOUS: a database for network-based drug-repositioning. Nucleic Acids Res. 39:D1060-66
128. Taboureau O, Nielsen SK, Audouze K, Weinhold N, Edsgard D, et al. 2011. ChemProt: a disease chemical biology database. Nucleic Acids Res. 39:D367-72
129. Chen B, Dong X, Jiao D, Wang H, Zhu Q, et al. 2010. Chem2Bio2RDF: a semantic framework for linking and data mining chemogenomic and systems chemical biology data. BMC Bioinform. 11:255
130. Qu XA,Gudivada RC, Jegga AG, Neumann EK, Aronow BJ. 2009. Inferring novel disease indications for known drugs by semantically linking drug action and disease mechanism relationships. BMC Bioinform. 10(Suppl. 5):S4
131. Ferrell JE Jr. 2009. Signaling motifs and Weber's law. Mol. Cell 36:724-27
132. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. 2009. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360:753-64
133. Li Y, Tesson BM, Churchill GA, Jansen RC. 2010. Critical reasoning on causal inference in genome-wide linkage and association studies. Trends Genet. 26:493-98
134. Chen BJ, Causton HC, Mancenido D, Goddard NL, Perlstein EO, Pe'er D. 2009. Harnessing gene expression to identify the genetic basis of drug resistance. Mol. Syst. Biol. 5:310
135. Chang RL, Xie L, Xie L, Bourne PE, Palsson BØ. 2010. Drug off-target effects predicted using structural analysis in the context of a metabolic network model. PLoS Comp. Biol. 6:e1000938
136. Obiol-Pardo C, Gomis-Tena J, Sanz F, Saiz J, Pastor M. 2011. A multiscale simulation system for the prediction of drug-induced cardiotoxicity. J. Chem. Inf. Model. 51:483-92
137. Khalili S, Monaco JM, Armaou A. 2010. Development of a stochastic model for the efficacy of NRTIs using known mechanisms of action. J. Theor. Biol. 265:704-17
138. Schmid A, Blank LM. 2010. Systems biology: hypothesis-driven omics integration. Nat. Chem. Biol. 6:485-87
139. Joyce AR, Palsson BØ. 2006. The model organism as a system: integrating 'omics' data sets. Nat. Rev. Mol. Cell Biol. 7:198-210
140. Palsson B, Zengler K. 2010. The challenges of integratingmulti-omic data sets. Nat. Chem. Biol. 6:787-89
141. Wiley HS. 2011. Integrating multiple types of data for signaling research: challenges and opportunities. Sci. Signal. 4:pe9